SAN DIEGO, May 9, 2019 /PRNewswire/ -- Immunic, Inc.
(Nasdaq: IMUX), a clinical-stage biopharmaceutical
company focused on developing best-in-class, oral therapies
for the treatment of chronic inflammatory and autoimmune diseases,
today announced that management will participate in the following
conferences in May:
- May 18-21: Digestive Disease
Week® (DDW): Dr.
Andreas Muehler, Chief Medical Officer of Immunic, will attend
the DDW conference, being held at the San
Diego Convention Center in San
Diego.
- May 20-21: BioEquity Europe
2019: Daniel Vitt, Ph.D., Chief
Executive Officer and President of Immunic, will present a company
overview at 5:15 pm CEST on
May 20 at the 20th Annual
BioEquity Europe conference, being held at the Crowne Plaza
Barcelona Fira Center Hotel in Barcelona,
Spain.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX)
is a clinical-stage biopharmaceutical company developing a
pipeline of selective oral immunology therapies aimed at treating
chronic inflammatory and autoimmune diseases, including ulcerative
colitis, Crohn's disease, relapsing-remitting multiple sclerosis,
and psoriasis. The company is developing three small molecule
products: IMU-838 is a selective immune modulator that inhibits the
intracellular metabolism of activated immune cells by blocking the
enzyme DHODH; IMU-935 is an inverse agonist of RORγt; and IMU-856
targets the restoration of the intestinal barrier function.
Immunic's lead development program, IMU-838, is in phase 2 clinical
development for ulcerative colitis and relapsing-remitting multiple
sclerosis, with an additional phase 2 trial in Crohn's disease
planned for 2019. An investigator-sponsored proof-of-concept
clinical trial for IMU-838 in primary sclerosing cholangitis is
planned to start at the Mayo Clinic. For further information,
please visit: www.immunic-therapeutics.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements" that involve substantial risks and uncertainties for
purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. All statements, other than
statements of historical facts, included in this press release
regarding strategy, future operations, future financial position,
future revenue, projected expenses, prospects, plans and objectives
of management are forward-looking statements. Examples of such
statements include, but are not limited to, statements relating to
Immunic's three development programs and the targeted diseases; the
potential for IMU-838, IMU-935 and IMU-856 to safely and
effectively target diseases; the nature, strategy and focus of the
company; and the development and commercial potential of any
product candidates of the company. Immunic may not actually achieve
the plans, carry out the intentions or meet the expectations or
projections disclosed in the forward-looking statements and you
should not place undue reliance on these forward-looking
statements. Such statements are based on management's current
expectations and involve risks and uncertainties. Actual results
and performance could differ materially from those projected in the
forward-looking statements as a result of many factors, including,
without limitation, risks and uncertainties associated with the
ability to project future cash utilization and reserves needed for
contingent future liabilities and business operations, the
availability of sufficient resources to meet business objectives
and operational requirements, the fact that the results of earlier
studies and trials may not be predictive of future clinical trial
results, the protection and market exclusivity provided by
Immunic's intellectual property, risks related to the drug
development and the regulatory approval process and the impact of
competitive products and technological changes. Immunic disclaims
any intent or obligation to update these forward-looking statements
to reflect events or circumstances that exist after the date on
which they were made.
Contact Information
Immunic, Inc.
Jessica
Breu
Manager IR and Communications
+49 89 250 0794 69
jessica.breu@immunic.de
Or
Rx Communications Group
Melody Carey
+1-917-322-2571
immunic@rxir.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/immunic-inc-to-participate-in-upcoming-may-conferences-300847151.html
SOURCE Immunic, Inc.